Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Cancer diagnostic and predictive biomarkers.

Buonaguro FM, Pauza D, Tornesello ML, Hainaut P, Franco R, Marincola FM.

Biomed Res Int. 2014;2014:980163. doi: 10.1155/2014/980163. Epub 2014 Apr 3. No abstract available.

2.

Response to comment on: 'evaluation of chemoresponse assays as predictive biomarkers'.

Korn EL, Freidlin B.

Br J Cancer. 2015 Jun 9;112(12):1978. doi: 10.1038/bjc.2015.157. Epub 2015 May 12. No abstract available.

3.

The search for optimal response prediction in cancer leads to a personalized approach.

Van Cutsem E, Ciardiello F.

Target Oncol. 2010 Mar;5(1):3-4. doi: 10.1007/s11523-010-0139-4. Epub 2010 Mar 28. No abstract available.

PMID:
20349283
4.

Comment on: 'evaluation of chemoresponse assays as predictive markers'.

Tian C, Gabrin MJ, Brower SL, Sargent DJ.

Br J Cancer. 2015 Jun 9;112(12):1977-8. doi: 10.1038/bjc.2015.156. Epub 2015 May 19. No abstract available.

5.

[Are expression signatures worthless?].

Jordan B.

Med Sci (Paris). 2012 May;28(5):547-50. doi: 10.1051/medsci/2012285022. Epub 2012 May 30. French. No abstract available.

6.

Advances and challenges in the use of biomarkers in clinical trials.

Chabner B.

Clin Adv Hematol Oncol. 2008 Jan;6(1):42-3. Review. No abstract available.

PMID:
18322440
7.

[Response predictive biomarkers to targeted therapies in oncology].

Harlé A, Merlin JL.

Ann Biol Clin (Paris). 2013 Nov;71:89-97. doi: 10.1684/abc.2013.0906. Review. French.

PMID:
24235332
8.

Advances in biomarkers for targeted agents.

Maitland ML.

Clin Adv Hematol Oncol. 2011 Sep;9(9):688-90. No abstract available.

PMID:
22402514
9.

Evaluation of chemoresponse assays as predictive markers.

Korn EL, Freidlin B.

Br J Cancer. 2015 Feb 17;112(4):621-3. doi: 10.1038/bjc.2014.661. Epub 2015 Jan 13.

10.

Qualification of imaging biomarkers for oncology drug development.

Waterton JC, Pylkkanen L.

Eur J Cancer. 2012 Mar;48(4):409-15. doi: 10.1016/j.ejca.2011.11.037. Epub 2012 Jan 5. Review.

PMID:
22226478
11.

Cancer epigenetics as biomarkers of clinical significance.

Panayiotidis MI.

Cancer Lett. 2014 Jan 28;342(2):168-9. doi: 10.1016/j.canlet.2013.10.027. Epub 2013 Oct 29. No abstract available.

PMID:
24183850
12.

Cancer biomarkers. Preface.

Dixit R, Srivastava S.

Cancer Biomark. 2005;1(1):3-4. No abstract available.

PMID:
17203571
13.

Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers.

Deng D, Liu Z, Du Y.

Adv Genet. 2010;71:125-76. doi: 10.1016/B978-0-12-380864-6.00005-5. Review.

PMID:
20933128
14.

Proteomics and translational medicine: molecular biomarkers for cancer diagnosis, prognosis and prediction of therapy outcome.

Cho WC.

Expert Rev Proteomics. 2011 Feb;8(1):1-4. doi: 10.1586/epr.10.108. No abstract available.

PMID:
21329422
15.

Plasma adenosine deaminase isoform 2 in cancer patients undergoing chemotherapy.

Roberts EL, Roberts OT.

Br J Biomed Sci. 2012;69(1):11-3.

PMID:
22558798
16.

Using bioanalysis for cancer diagnosis and prognosis.

Markuszewski MJ, Kaliszan R.

Bioanalysis. 2014 Apr;6(7):907-9. doi: 10.4155/bio.14.38. No abstract available.

PMID:
24806899
17.

Great potential of miRNAs as predictive and prognostic markers for cancer.

Cho WC.

Expert Rev Mol Diagn. 2012 May;12(4):315-8. doi: 10.1586/erm.12.21. Review. No abstract available.

PMID:
22616694
18.

Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum.

Brenner DE, Normolle DP.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1918-20. No abstract available.

19.

Assessment of predictive values of tumor markers.

Roulston JE.

Methods Mol Med. 2004;97:13-27. Review. No abstract available.

PMID:
15064482
20.

Supplemental Content

Support Center